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Although safety concerns preclude the use of live attenuated HIV vaccines in humans, they provide a
useful system for identifying the elusive correlates of protective immunity in the SIV/macaque animal
model. However, a number of pieces of evidence suggest that protection may result from prior occu-
pancy of susceptible target cells by the vaccine virus rather than the immune response. To address this,
we developed a Nef-deletion variant of an RT-SHIV whose active replication could be shut off by
treatment with RT-inhibitors. Groups of macaques were inoculated with the ΔNef-RT-SHIV and
immune responses allowed to develop before antiretroviral treatment and subsequent challenge with
wild-type SIVmac239. Vaccinated animals either resisted infection fully or signiﬁcantly controlled the
subsequent viremia. However, there was no difference between animals undergoing replication of the
vaccine virus and those without. This strongly suggests that competition for available target cells does
not play a role in protection.
& 2015 Elsevier Inc. All rights reserved.Introduction
The most consistently effective forms of vaccine tested in the
SIVmac/macaque animal model for AIDS have been those based on
live attenuated variants of the pathogenic virus. Such live atte-
nuated vaccines, usually containing deletions in the non-essential
regulatory nef gene, have been shown in many studies to protect
from subsequent challenge with wild-type SIVmac (Cranage et al.,
1998; Daniel et al., 1992; Nilsson et al., 1998; Norley et al., 1996;
Wyand et al., 1996). However, early hopes of developing corre-
sponding live attenuated HIV vaccines were dashed when it
became clear that such 'vaccines' can themselves cause AIDS in
macaques (rapidly in neonates and eventually also in adults (Baba
et al., 1999; Hofmann-Lehmann et al., 2003)) and that humans
infected with naturally occurring nef-deletion mutants of HIV can
also succumb to disease (Learmont et al., 1999). Although live
attenuated AIDS vaccines cannot therefore be used in humans,
identifying the biological mechanisms responsible for protectionork.might provide insights that would facilitate the targeted devel-
opment of safe forms of vaccines able to induce the same (pre-
sumed) immune responses. Indeed, the concept that persistently
replicating attenuated viruses or viral vectors are able to induce
the mature types of immune responses needed for protection from
infection has recently been bolstered by the success seen in the
macaque animal model using replication-competent cytomegalo-
virus (CMV) vectors carrying SIV genes, in which vaccinated ani-
mals were shown to control infection with pathogenic SIVmac
(Hansen et al., 2009) and even to eventually clear the virus
(Hansen et al., 2013).
Despite intense efforts, all attempts to identify the protective
immune mechanism induced by deletion mutants of SIV have so
far yielded equivocal results. Initial studies with viruses containing
large deletions in Nef suggested that maturation of high avidity
anti-Env antibodies over a long period was required (Cole et al.,
1997). However, protection has been achieved by us and others
using an SIV carrying a small Nef deletion (C8) in only 10 weeks or
less (Norley et al., 1996; Stebbings et al., 2004) and a comparison of
immune responses did not reveal a clear 'correlate of protection'.
Furthermore, passive transfer of antibodies from 'immunized'
macaques does not confer protection (Almond et al., 1997) and
similarly, depletion of CD8þ T-cells does not abrogate protection
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animals 'vaccinated' with an attenuated SIV resist superinfection
by exogenously delivered wild-type virus but allow the attenuated
vaccine virus to mutate back to the same pathogenic form
(Whatmore et al., 1995). These observations are difﬁcult to
reconcile with the concept of immunity-based protective
mechanisms.
It therefore seemed possible that, rather than inducing pro-
tective immune responses, live attenuated viruses prevent super-
infection by active competition for 'infectible' target cells. In this
scenario, the attenuated viruses would become established in
lymphoid tissues where all freshly activated cells would immedi-
ately become infected. The cells in circulation encountering the
injected challenge virus would then be either not susceptible to
infection or already infected with the vaccine virus.
Distinguishing between mechanisms of immunity and those of
competition is difﬁcult because the strength of the immune
response often depends on the degree of virus replication. Hence,
highly attenuated forms of SIV do not replicate well but also do not
induce vigorous immune responses (Johnson et al., 1999; Wyand
et al., 1996). Simple correlations therefore fail to address the
question of mechanism in an independent manner.
In order to tackle the question of mechanisms of protection, it
is therefore necessary to uncouple immune responses from virus
replication. As mentioned above, passive antibody transfer or T-
cell depletion experiments have failed in this respect. We there-
fore developed a systemwhereby a live attenuated virus is allowed
to stimulate the full repertoire of immune responses before having
its replication 'shut-off', leaving the immune responses to act
alone against the challenge virus. An SIVmac Δnef RT-SHIV was
produced that expresses the HIV reverse transcriptase in place of
the SIV enzyme and carries a large 181 bp deletion in the nef gene.
This was shown to be highly susceptible to the antiviral effects of
non-nucleoside RT-inhibitors such as Nevirapine, in contrast to
wild-type SIV that is not affected by this therapeutic. This allows
replication of the vaccine virus in immunized macaques to be shut
off by intensive antiretroviral treatment before challenge with the
ART-resistant wild-type SIVmac. If competition between vaccine
and challenge viruses is indeed responsible for the protective
efﬁcacy of live attenuated SIV, ART-treated animals should be
rendered susceptible to infection despite the presence of a vigor-
ous antiviral immune response.Results
Vaccination phase
Eight rhesus macaques were infected with the Δnef-RT-SHIV
(SIVmac239 carrying the RT from HIV and a 181 bp deletion in
nef). Plasma virus loads, as measured by qRT-PCR, were very low
during the acute phase (near or under the detection limit) but
replicating virus could be reisolated from all animals. By 28 weeks
post-infection (wPI), however, even cocultivation failed to
yield virus.
In terms of humoral immune response, all but one (Rh08)
seroconverted by week 6 and by week 16 all were antibody
positive (Fig. 1A). Despite the lack of detectable virus and with the
exception of Rh08, antibody responses generally increased or
remained stable during the second half of the 'vaccination' phase,
indicating an ongoing, low level of virus production throughout
this period. Although appearing later, antibodies with high avidity
were measurable in all animals by 16 wPI and avidities remained
stable or increased during the rest of the vaccination phase
(Fig. 1B).Antibodies able to neutralize SIVmac generally developed by 16
wPI (Fig. 1C), although Rh04 was positive for neutralizing anti-
bodies by 6 wPI and plasma from Rh03, Rh06 and Rh08 only
sporadically contained low levels of neutralizing antibodies during
the vaccination phase. Antibodies able to mediate ADCC of SIVmac
infected cells were detected as early as 8 wPI in most animals
(Fig. 1D), although levels ﬂuctuated throughout the vaccination
phase thereafter.
Virus-speciﬁc T-cell responses, as measured by IFNγ ELISpot
using overlapping peptides as stimulants, developed slowly during
the 'vaccination' phase (data not shown) but by the time of chal-
lenge at week 48, all animals showed speciﬁc responses, with
those to Gag or Pol predominating (Fig. 4).
Treatment phase
Starting at 40 wPI, immunized animals in group A and non-
immunized animals in group C received oral Nevirapine treatment
daily. Although it had originally been planned to challenge the
animals at week 44, the Nevirapine levels in the plasma of the
macaques were found on two occasions to be lower than that
recommended for treating HIV infection in humans (Table 1).
Increasing the dose administered daily did not succeed in sufﬁ-
ciently boosting these levels. As plasma virus loads were already
under the detection limit before treatment, it was not possible to
directly measure the effects of ART on virus replication. Treatment
was therefore switched to a second NNRTI, Efavirenz, that has the
same target as Nevirapine but which would potentially be taken
up systemically with a higher efﬁciency. In vitro assays in which
virus replication was completely abrogated in the presence of
plasma (diluted 1:5) from the treated animals demonstrated that
the macaques had sufﬁcient drug in circulation to suppress repli-
cation of the RT-SHIV (Fig. 2A). Indeed, the plasma from most
animals showed near-maximal suppression of virus replication
in vitro even when diluted 1:80 (Fig. 2B). All animals were there-
fore challenged intravenously with 100 MID50 of SIVmac239 at
week 48. Treatment with Efavirenz continued during the ﬁrst four
weeks after challenge.
Post-challenge phase
Plasma virus loads
One week post-challenge (wPC), all non-vaccinated control
animals (groups C and D) had detectable virus loads in plasma
(qRT-PCR) whereas only two immunized animals (both in group B)
were positive (Fig. 3). By 2 wPC, two animals in group A and a
further animal in group B became positive. By week 3, one further
animal was positive. A complete lack of evidence for challenge
virus replication was only seen in two macaques, Rh01 and Rh06
from groups A and B, respectively.
Despite a general lack of complete protection there was a
strong vaccine effect. Peak virus loads in 'vaccinated' macaques
were 2–3 orders of magnitude lower than in control animals and
by 4 wPC, ﬁve of the seven virus positive animals in the vaccina-
tion groups were again negative (median virus loads reduced by a
factor of at least 5103 compared to controls). Comparing peak
virus loads and 'set-point' virus loads (mean of weeks 8–16)
between vaccinated and control animals by one-way ANOVA gave
p-values of o0.0001 for both. Animal Rh08 was euthanized at
week 6 due to a long-standing tumor unrelated to the infection. By
10 wPC, all remaining vaccinated animals were virus-negative (i.e.
plasma virus loads under the detection limit). Such a pattern of
low-level, transient plasma virus load after challenge has been
described previously in SIVmac vaccine studies, including a
number using live attenuated vaccines (Hansen et al., 2011;
Johnson et al., 1999; Mascola et al., 2003; Wyand et al., 1996). Most
Table 1
HPLC analysis of plasma samples from ART-treated monkeys during the ART-
treatment phase between weeks 40 and 52.
Nevirapine (ng/ml) Efavirenz (ng/ml)
Rhesus 42 wpi 43 wpi 45 wpi 48 wpi 50 wpi 52 wpi
01 446 875 270 425 207 221
02 128 885 120 248 97 68
03 99 140 236 502 398 244
04 104 174 268 350 36 20
09 392 332 267 569 250 634
10 199 108 188 598 0 674
11 1306 695 375 178 63 832
12 1069 624 384 709 51 572
Fig. 1. Humoral immune responses to SIV. (A) Titers of virus-speciﬁc IgG as measured by ELISA. (B) Analysis of the avidity of virus-speciﬁc IgG by ELISA in the presence or
absence of 8 M urea. The avidity index (AI%) was calculated as the ratio of signals from urea-treated and non-treated wells. (C) Detection of antibodies able to neutralize
SIVmac251. Yield reduction is calculated as the titer of virus in the absence of plasma divided by the titer in the presence of plasma. (D) Levels of antibody-dependent cell-
mediated cytotoxicity (ADCC). SIV-infected CEM.NKR-CCR5 were double-labeled (cytoplasm and membrane) and incubated with plasma samples in the presence of effector
cells before measurement of lysed cells by FACS. Percent ADCC is calculated as the % lysis of infected cells minus % lysis of uninfected cells.
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cation by ART had diminished the ability of the immunized
macaques in group A to resist infection by the challenge virus.
Virus replication in lymph nodes
Diagnostic PCR analysis of lymph node tissue taken at 4 wPC
revealed that at the RNA level, wild-type challenge virus was
present in all animals except Rh01 and Rh06 (Table 2). This agreeswith the virus load data, particularly the very low or absent
plasma loads and lack of anamnestic antibody response in the two
negative animals (Figs. 3 and 1A). Cocultivation also failed to yield
challenge virus in these two animals (Table 2), although the vac-
cine virus was present in the culture from Rh01 and a mixed
infection was seen in the culture from Rh07. Surprisingly, with the
exception of Rh08, direct PCR of provirus in lymph node cells was
negative for challenge virus but positive in ﬁve animals for the nef-
deleted vaccine virus.
Analysis of immune responses
Humoral immune responses, as measured by ELISA, showed
that most control animals showed early evidence of SIV-speciﬁc
antibodies, most at 4 wPC and one (Rh 09) at 6 wPC (Fig. 1A). The
one clear exception was Rh16 that showed no sign of SIV-speciﬁc
antibodies until the last bleeding at 16 wPC. This was not due to a
delayed or low-level virus infection as this animal showed levels of
viremia 1–2 orders of magnitude higher than the other animals
from 6 wPC onwards. The failure to develop high titer antibody
responses would therefore appear to be due to a 'crash-and-burn'
course of infection as described previously (Zhang et al., 1988).
With the exception of Rh01 and Rh06, which remained virus
negative after challenge, animals in the vaccine groups showed an
Fig. 2. Inhibition of virus replication by plasma isolated from monkeys undergoing
antiretroviral therapy. C8166 cells were infected (with either Δnef-RT-SHIV or
SIVmac239) before addition of plasma at various dilutions. Virus replication (pro-
viral DNA copies) was measured by real-time PCR after 72 h. (A) Speciﬁc inhibition
of Δnef-RT-SHIV replication in vitro. A 1:5 dilution of plasma from ART-treated
animals at week 48 was used to speciﬁcally inhibit the replication of the RT-SHIV
virus. (B) Inhibitory effect of plasma samples from ART-treated animals at the time
of challenge. Plasma from treated macaques (groups A and C) was titrated in 2-fold
dilutions starting at 1:5. For animals of groups B and D (non-treated), only the 1:5
dilution of plasma was used.
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compared to control animals that remained seronegative until
week 4 (po0.01, chi-square test). Antibody avidities after chal-
lenge showed no distinct pattern of change, decreasing slightly in
the animals with no evidence of challenge virus replication (Rh01
and Rh06), but also in animals Rh03 and Rh08, or continuing to
rise or remaining stable in the others. Control animals had only
started to develop high-avidity antibodies by the end of the
experiment (Fig. 1B).
Similar to the situation with binding antibodies, levels of neu-
tralizing antibodies in all six vaccinated animals with evidence for
challenge virus replication showed an anamnestic response
(po0.01, chi-square), with increases in titer of one to two orders
of magnitude (Fig 1C). Most of the control animals also showed a
rapid development of neutralizing antibodies, becoming positive
by 4 or 6 wPC (8 wPC for Rh 10). As could be expected from the
pattern of binding antibodies, Rh16 failed to develop any detect-
able neutralizing antibodies.
Levels of antibody able to mediate ADCC of SIV infected cells
showed a similar pattern to that of binding and neutralizing
antibodies: an anamnestic response in the vaccinated but super-
infected animals, no such response in the non-viremic animals and
the rapid development of such antibodies in all control animals
except Rh16.
Speciﬁcity of the antibody response
Samples of plasma taken before and after 'vaccination' and chal-
lenge were analyzed by Western blot (Table 3). Pre-vaccinationsamples showed no evidence for SIV-speciﬁc antibodies but by the
time of challenge at 48 weeks, all but Rh08 showed antibodies to Env
glycoprotein and, with the exception of Rh05, the Gag proteins p27
and p17. The high background signal with plasma from Rh08 against
both infected and uninfected cell lysates precluded identiﬁcation of
individual reactivities. As early as one week after challenge with the
SIVmac239 wild-type virus, responses to the proteins strengthened in
the vaccinated but superinfected macaques (i.e. Rh02, Rh03, Rh04,
Rh05, Rh07). In accordance with the ELISA data, speciﬁc antibodies
appeared later in the control animals (groups C and D) and responses
were very strong by 16 wPC (with the exception of Rh16 that
remained seronegative) with a broad speciﬁcity, recognizing Env, Pol
(p31 and p66) and Gag (p17, p27 and p55). In contrast, 'vaccinated'
animals showed only slight changes in speciﬁcity, with antibodies
against p55 appearing after the challenge to supplement the pre-
existing antibodies measured before.
Cellular responses
At the time of challenge, the highest T-cell responses as mea-
sured by ELISpot were seen in Rh06, one of the animals that
apparently resisted superinfection with the challenge virus.
However, Rh01 (that also resisted superinfection) had the lowest
frequency of speciﬁc T-cells (Fig. 4). The fact that Rh05 had the
strongest T cell response of the vaccinated macaques after chal-
lenge and was also the ﬁrst monkey in group B to suppress virus
replication under the detection limit might suggest a role for T cell
activity. However, this correlation does not hold true for Rh07
and R03.
Besides ELISpot, the frequencies of T cells recognizing the
Mamu-A01-restricted, immunodominant SIVmac Gag CM9 epi-
tope were measured using tetramers. All animals of the 'vacci-
nated’ groups developed CM9-speciﬁc T cells before challenge.
Indeed, the non-viremic animals, Rh01 and Rh06, had the highest
frequencies of tetramer positive cells (Fig. 5). Following challenge,
these frequencies further increased in the ‘vaccinated’ animals and
appeared in the control animals, so that by week 16 wPC any
difference between the control groups and the ‘vaccinated’ groups
had disappeared.
Cytokine proﬁles
Cytokine proﬁles were measured in plasma samples taken
between weeks 0 and 4 post-challenge. Of the 23 cytokines ana-
lyzed, only a few differed between the vaccinated and control
animals (Fig. 6), i.e. levels of IL-15 and MCP-1, peaked at around
2 wPC in the control animals but not in the vaccinated animals.
This may reﬂect the control of virus replication in the vaccinated
animals, as these cytokines play important roles in immune acti-
vation (cell activation, T cell recruitment).Discussion
Despite their inherent dangers that preclude their use in
humans, there is no doubt that live-attenuated vaccines have
historically been the most successful strategy for inducing pro-
tective immunity in the non-human primate model for HIV/AIDS
(Almond et al., 1995; Berry et al., 2011; Cranage et al., 1997; Daniel
et al., 1992; Johnson et al., 1999; Lohman et al., 1994; Nilsson et al.,
1998; Norley et al., 1996; Stahl-Hennig et al., 1996; Wyand et al.,
1996). Many efforts to identify the mechanism of protection have
been made, but the underlying biological reason for their success
remains a matter of debate. One problem with such studies is that
the observed correlates of protective immunity appear to depend
on the nature of the vaccine virus, the challenge virus and the
assays used. For example, early results using a vaccine virus with a
Fig. 3. Levels of viral RNA, measured by qRT-PCR, in the plasma of vaccinated (groups A and B) and control animals (groups C and D) following challenge with wild-type
SIVmac239. Both peak loads and set-points were signiﬁcantly lower in vaccinated animals compared to controls (po0.0001).
Table 2
Detection of RNA and provirus DNA in lymph node biopsies four weeks post-
challenge. Lymph nodes from animals of group A and B were analyzed for the
presence of RT-SHIV and wild-type SIV four weeks after challenge. Nucleic acids
were detected by diagnostic PCR on either fresh isolated DNA or RNA, or on co-
culture samples. ◌, no detection, ●, nucleic acid detected.
Proviral DNA Viral RNA
Lymph node Co-culture Lymph node
Rh RT-SHIV SIVmac239 RT-SHIV SIVmac239 RT-SHIV SIVmac239
01 ● ○ ● ○ ○ ○
02 ○ ○ ○ ● ○ ●
03 ● ○ ○ ● ○ ●
04 ● ○ ○ ● ○ ●
05 ● ○ ○ ● ○ ●
06 ○ ○ ○ ○ ○ ○
07 ● ○ ● ● ○ ●
08 ○ ● ○ ● ○ ●
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avidity antibodies over a period of 40 weeks was associated with
protection (Cole et al., 1997). However, later studies using a virus
with a small deletion in nef (that nevertheless rendered the pro-
tein inactive) demonstrated protection after only 10–20 weeks of
'immunization' (Norley et al., 1996) or even earlier (Stebbings
et al., 2004). Studies using a live SIV attenuated by deglycosylation
failed to ﬁnd any correlation between levels of neutralizing anti-
bodies or T-cell responses and containment of acute and chronic
viral replication (Sugimoto et al., 2010). Active intervention such as
depletion or transfer is often more revealing than a simple search
for correlations, and to this end a number of studies have
attempted this in the live attenuated virus vaccine/macaquemodel. Transfer of immune serum from immunized macaques
failed to protect recipients from subsequent challenge (Almond
et al., 1997), suggesting that none of the antibody-mediated
mechanisms (neutralization, ADCC etc.) play a critical role in
protection, although experiments with viruses mismatched in Env
did suggest a role in early protection (Manrique et al., 2013).
Depletion of CD8þ cells from macaques immunized with an
attenuated SIVmacΔ3 virus, despite some hints of reduced efﬁcacy,
failed to demonstrate a signiﬁcant effect on viral loads upon
challenge (Schmitz et al., 2005) although others (Genesca et al.,
2008) using an attenuated SHIV as a vaccine and challenging
intravaginally showed a loss of protection after CD8-depletion.
Although very difﬁcult to achieve in outbred macaques, adoptive
transfer of lymphocytes from immunized macaques to MHC-
matched naïve recipients prior to challenge has been success-
fully carried out but failed to inﬂuence the peak and set-point viral
loads (Greene et al., 2013).
These and other lines of evidence (Sharpe et al., 1997; What-
more et al., 1995) suggested that protection was possibly being
mediated by occupation of potential target cells by the vaccine
virus rather than by the immune responses induced. Distinguish-
ing between these two mechanisms, immune responses or
blockade, is difﬁcult because the levels of immune response often
depend on the degree of prior virus replication. It would appear to
be necessary to uncouple immunity from replication. Others have
generated conditionally-replicating SIVs (and nef-deletion mutants
thereof) to provide a 'safe' form of attenuated vaccine and to
uncouple replication from immune response (Berkhout et al.,
2002; Das et al., 2008, 2007; Manoussaka et al., 2013; Xiao et al.,
2000), but results of challenge studies using such constructs have
yet to be published.
Table 3
Determination of the speciﬁcities of IgG antibodies found in plasma samples before and after challenge. Identiﬁcation of antibodies using Western blot strips containing SIV
proteins from infected cells. Empty ﬁelds, no assay performed, ◌, protein not detected, ●, protein detected.
Rhesus
01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
Pre-challenge gp160 ● ● ● ● ● ● ● ○
gp120 ● ● ● ● ● ● ● ○
gp80 ○ ○ ○ ○ ○ ○ ○ ○
p66 ○ ○ ○ ○ ○ ○ ○ ○
p55 ○ ○ ○ ○ ○ ○ ○ ○
gp41 ○ ○ ○ ● ○ ○ ○ ○
p31 ○ ○ ○ ○ ○ ○ ○ ○
p27 ● ● ● ● ● ● ● ○
p17 ● ● ● ● ○ ● ● ○
Post-challenge gp160 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ○
gp120 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ○
gp80 ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ● ○ ● ○ ○ ○
p66 ○ ○ ○ ● ○ ○ ○ ○ ○ ● ● ● ● ● ● ○
p55 ○ ● ● ● ● ○ ● ● ● ● ● ● ● ● ● ○
gp41 ○ ● ● ● ● ○ ● ● ● ● ● ● ● ● ● ○
p31 ○ ○ ○ ○ ○ ○ ○ ○ ● ● ● ● ● ● ● ○
p27 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ○
p17 ● ● ● ● ● ○ ● ● ● ● ● ● ● ● ● ○
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virus whose replication could be 'turned off' before challenge,
leaving the immune responses predominantly unaffected. A
181 bp deletion (similar to that described by Kestler et al. (1991))
was introduced into the nef gene of a modiﬁed SIV (kindly pro-
vided by Prof. Klaus Überla, Erlangen, Germany) that had its cod-
ing sequence for reverse transcriptase replaced with that of HIV-1,
rendering it susceptible to RT-speciﬁc antiretroviral drugs (Uberla
et al., 1995), unlike wild-type SIV.
Eight rhesus macaques were inoculated with this Δnef-RT-SHIV
and, similar to earlier studies, immune responses were allowed to
develop for over 40 weeks. During this period, cellular and
humoral immune responses and virological parameters were
monitored on a regular basis. The pattern and levels of viremia
conﬁrmed the highly attenuated phenotype of the vaccine virus,
with very low initial peaks of viral load that rapidly dropped
below the limit of detection.
The extremely low (i.e. undetectable) levels of 'set-point' vir-
emia suggest that the Δnef-RT-SHIV is even more attenuated in its
replication potential than the 'wild-type' Δnef-SIVmac239 that it is
based upon. This is not surprising given the probable sub-optimal
functioning of the HIV reverse transcriptase within the context of
an SIV background, but this further attenuation likely impacts the
protective efﬁcacy of the 'vaccine' virus. A number of studies have
demonstrated a negative correlation between the degree of SIV
attenuation and the protective effect induced (Johnson et al., 1999)
This inability to measure levels of virus replication made it
difﬁcult to conﬁrm the efﬁcacy of the antiretroviral drugs when
treatment commenced at 40 wPI. Although previous studies had
clearly demonstrated the suppression of RT-SHIV replication
in vivo by RT-inhibitors (Uberla et al., 1995), it was nevertheless
important to have evidence (direct or indirect) for this effect with
the Δnef-RT-SHIV before challenge with the wild-type SIVmac239.
Addition to infected cell cultures of plasma from treated maca-
ques, even at ﬁnal dilutions as high as 1:80 severely abrogated the
ability of the virus to replicate (Fig. 2A and B). The evidence
therefore indicated that replication of the vaccine virus in the
'vaccinated' macaques was indeed suppressed by the antiretroviral
drug treatment and all animals were challenged with the wild-
type SIVmac. The fact that antiretroviral treatment is able to
suppress active replication of RT-SHIVs in all relevant tissues was
recently conﬁrmed at necropsy (Kearney et al., 2015).Only two animals (Rh01 and Rh06) had a complete lack of
virologic and immunologic evidence for challenge virus replica-
tion. This degree of protection was somewhat less than would be
expected with a standard Δnef-SIVmac239 vaccine (Daniel et al.,
1992), but given the expected (and observed) increase in
attenuation in the Δnef-RT-SHIV is not surprising. All remaining
vaccinated (but superinfected) animals showed levels of viremia,
in terms of both peak phase and set-point, that were drastically
reduced compared to the control animals (Fig. 3). Indeed, by
8 wPC, levels of viremia remained under the detection level for all
animals except Rh02 that showed occasional low level 'blips' of
viremia. As expected, control animals showed peak viral loads of
between 105.5 and 107 RNA copies/ml and, with one exception,
high set-points.
The most important outcome of the challenge was the fact that
there was no obvious difference in the degree of protection seen in
the ART-treated and untreated vaccine groups. Both groups had
one animal showing no evidence of challenge virus replication and
otherwise similar degrees of virus control. Suppressing vaccine
virus replication therefore did not abrogate protective efﬁcacy. The
central hypothesis addressed by the study, i.e. that the protection
observed with attenuated SIV vaccines is due to competition for
susceptible target cells, would therefore appear to be falsiﬁed. A
recent publication by Berry et al. (2015) also suggests that per-
sistence of the vaccine virus, rather than target cell occupancy, is
needed for the protective effect. In all, these data suggest that
some aspect of the adaptive or innate immune system (or com-
bination thereof) is indeed responsible for protection.
The antibody levels induced by the attenuated RT-SHIV were
moderate, and their maintenance (or gradual increase) is con-
sistent with an ongoing, low level infection, despite viral loads
being under the detection limit. The two animals showing no
evidence of challenge virus replication had responses at the time
of challenge that were near or at the low end of the distribution
for vaccinees. Furthermore, the lack of a vigorous anamnestic
response, in contrast to that seen with the vaccinated but
challenge-virus positive macaques, underscores their lack of sig-
niﬁcant challenge virus replication.
Although our study allowed time for the development of high
avidity, neutralizing antibodies, no difference between the subse-
quently viremic and non-viremic animals with regard to antibody
avidities was observed (Fig. 1B). Furthermore, the SIVmac239 used
Fig. 4. Enumeration of SIV-speciﬁc IFN-γ producing T cells. ELISpot assays were
performed using PBMCs and pools of overlapping peptides corresponding to dif-
ferent SIV proteins. The graphs indicate the sum of all responses at the time of
challenge (week 48) and at 16 weeks post-challenge. Due to a limited number of
cells, Env and Nef pools were excluded from the analysis at week 48.
Fig. 5. Determination of SIV-speciﬁc CD8þ T cells using Mamu-A01 tetramers
loaded with the SIVmac Gag CM9 peptide. Total PBMCs from animals were stained
with tetramers and with ﬂuorescently-labeled antibodies against CD3, CD4, and
CD8. The proportions of CM9-speciﬁc CD8þ T cells are shown at three different
time points. Animals are shown according to their groups. Animals showing no
evidence of challenge virus replication are indicated in red, those eventually con-
trolling the infection in green and those with fulminant infection in purple. Rh 08
(group B, light purple) was euthanized too early to allow classiﬁcation. An example
of one tetramer staining is shown in the ﬁrst panel.
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tant' (Horton et al., 2002), but even the levels of neutralizing
antibodies measured in vitro using the neutralization-susceptible
SIVmac251 strain did not correlate with protection (Fig 1C).
Indeed, the two animals (Rh01 and Rh06) that showed no sign of
challenge virus replication had undetectable titers of neutralizing
antibodies on the day of challenge in contrast to most of the other,
viremic macaques.
Neutralization is not the only effector mechanism initiated by
antibodies however, and recently there has been a resurgence in
interest in the possible role played by antibody-dependent cellular
cytotoxicity (Haynes et al., 2012; Hessell et al., 2007). However, in
our study, the pattern of ADCC antibodies generally followed those
of binding and neutralizing antibodies, and no obvious role in
protection could be seen (Fig. 1D).T-cell responses as measured by γ-IFN ELISpot assay did not
appear to be responsible for the protective effect as there was no
trend separating the viremic from the non-viremic animals (Fig. 4).
Although the subsequently non-viremic animal Rh06 had the
highest ELISpot responses on the day of challenge, the other
(Rh01) had the lowest responses of all. We also analyzed the SIV-
speciﬁc CD8þ T-cell response with the help of CM9-tetramers and
identiﬁed SIV-speciﬁc CD8þ T-cells in all vaccinated animals at
different frequencies (Fig. 5). Interestingly, the two subsequently
non-viremic animals showed prechallenge tetramer positive CD8þ
cell frequencies that were higher than the other vaccinated ani-
mals, although this difference was not signiﬁcant.
Fig. 6. Differences in plasma cytokine concentration between the monkeys of the
vaccinated groups (A, B) and the control animals (C, D). Four out of the 23 analyzed
cytokines during the ﬁrst ﬁve weeks post-challenge showed clear differences
between the two groups. Differences are shown as n-fold change, and were sig-
niﬁcant for two cytokines, IL-15 and MCP-1 (po0.05).
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immunity could be identiﬁed in the macaques involved in this
study, plasma levels of 23 different cytokines at the time of chal-
lenge and shortly thereafter were compared in Group A (vacci-
nated and treated) and Group C (unvaccinated and treated) ani-
mals with a view to gaining some insight into possible innate
mechanisms of protection (Fig. 6). Although some cytokines such
as IL-4, IL-12 and MIP-1ß were indeed higher in the one non-
viremic animal (Rh01), it was not possible to draw any ﬁrm con-
clusions about possible roles in protection.
In conclusion, the major ﬁnding of this study was that by
uncoupling the immune response from virus replication it was
possible to demonstrate that the protection induced by a live
attenuated SIV was not dependent on the ongoing replication of
the vaccine virus. This refutes the hypothesis that competition for
(or occupancy of) available target cells is a major contributor to
protecting against subsequent infection with a full-length patho-
genic SIVmac. This therefore leaves open the possibility that the
real but elusive mechanisms of protection will eventually allow
vaccine efforts to focus on the stimulation of such responses in a
safe manner. Additional studies speciﬁcally aimed at the careful
and precise analysis of the immune status of vaccinated animals
remain essential in helping resolve this important issue.Materials and methods
Construction and in vitro characterization of the Δnef-RT-SHIV
The construction of the pBR-RT-SHIV (DNA kindly provided by Dr.
Klaus Überla) has been described previously (Uberla et al., 1995). The
molecular clone consists of the SIVmac239 (M33262) genome carrying
the reverse transcriptase (RT) of HIV-1 HXB2 in place of the original
SIV sequence. In order to prepare a Nef-deletion corresponding to that
described by Kestler et al. (1991), a nef containing fragment was
excised from the plasmid using the NheI and EcoRI restriction sites
and ligated into the cloning vector pCR3.1-uni (Invitrogen). Using this
as template, two PCR fragments were produced (T7 primer and nef-
del_Rev: ATG AGA CAC TGT CCC TCA CAA GAG AGT G; nef-del_For:
AGG GAC AGT GTC TCA TTT TAT AAA AGA AAA GGG GGG and BGH
reverse primer), fused together with a subsequent PCR to generate
Δ181-nef and then cloned back in pCR3.1-uni.
To replace the original nef sequence from RT-SHIV with Δ181-
nef, the RT-SHIV was digested using HindIII and religated to create
pBR-RT-SHIV-env/nef/3LTR. Using NheI and EcoRI, nefwas replaced
with the corresponding fragment from pCR3.1-Δ181-nef. Finally,
the env/Δ182-nef/3LTR part of the RT-SHIV genome was reinserted
into pBR-RT-SHIV using NheI and BglI and the resulting RT-SHIV
Δnef clone was conﬁrmed by sequencing and by analyzing the
replication capacity in vitro using Cos7, C8166 cells and
rhesus PBMCs.
Animal experiments
The 16 rhesus macaques were housed in the animal facilities of
the Paul-Ehrlich-Institute in Langen, Germany. The relevant animal
experimentation and gene technology licenses were, in accor-
dance with German law, obtained before the start of the experi-
ment. All animals were genotyped as Mamu-A*01 positive.
The macaques were divided into four groups. Groups A and B
were to be 'vaccinated' with the Δnef-RT-SHIV while groups C and
D served as non-vaccinated controls. Groups A and C were to
receive antiretroviral therapy with groups B and D acting as
therapy controls.
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groups A and B were 'vaccinated' intravenously with 1 ml of cul-
ture supernatant containing 2106 TCID50 of the Δnef-RT-SHIV.
This virus stock was produced on rhesus PBMC, aliquoted, and
stored in liquid nitrogen until use. At regular intervals before and
after inoculation, blood samples were taken and processed to yield
plasma and PBMC. Brieﬂy, macaques were anesthetized and 8–
16 ml blood were collected in vacutainer tubes containing sodium
citrate and separated by density centrifugation (Histopaque-1077
Hybri-Max; Sigma-Aldrich Corp., St. Louis, MO, USA). Plasma was
aliquoted and stored at 80 °C, and PBMCs, treated with ACK
buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA) to remove
residual erythrocytes if necessary, were either used immediately
for ELISpot or co-cultivation and/or cryopreserved in liquid nitro-
gen using Cryo-SFM (PromoCell, Heidelberg, Germany).
Starting at 40 weeks, animals of groups A and C received daily
oral doses of 4 mg/kg of the non-nucleotide RT-inhibitor Nevir-
apine (Viramune, Boehringer Ingelheim, Ingelheim, Germany). The
appropriate quantity of antiretroviral was mixed with vitamin
syrup and delivered to the macaques manually. Plasma levels of
the antiretroviral drug were monitored regularly by HPLC (Prof. H.
Klinker, Center for Infectiology, University Hospital of Würzburg)
and, due to unexpectedly low plasma concentrations, the dose of
Nevirapine was increased to 7 mg/kg. At week 44 the NNRTI Efa-
virenz (Sustiva, Bristol-Myers Squibb, New York, USA) was sub-
stituted for Nevirapine to avoid continuing problems with drug
levels. Doses started at 10 mg/kg and were elevated at week 47 to
20 mg/kg.
At week 48 (0 wPC), all animals were challenged by intrave-
nous inoculation of 100 monkey infectious doses (MID50) of wild-
type SIVmac239 (kindly provided by Christiane Stahl-Hennig,
German Primate Centre, Göttingen). This virus stock had been
grown in rhesus PBMC and titrated intravenously in macaques
(106 MID50/ml). Antiretroviral drug treatment continued until
week 52 (4 wPC) and blood samples were taken at regular inter-
vals until week 64 (16 wPC) at which time the animals were
euthanized.
Measurement of virus loads
Plasma viral loads were determined by real-time PCR of RNA
extracted and concentrated from plasma (High Pure Viral RNA Kit;
Roche, Penzberg, Germany) using primers and a probe speciﬁc for
SIVmac gag (AVF primer: CTA GTG GTG GAA ACA GGA ACA; AVR
primer: TGT TCT CGG GCT TAA TGG CA; AVP probe: [FAM] CCA
ACA GCA CCA TCT AGC GGC AGA GGT [BBQ]). The RT-qPCR of RNA
was performed using the OneStep RT-PCR Kit (Qiagen, Hilden,
Germany). Using serial dilutions of plasmid DNA corresponding to
full-length SIVmac, the sensitivity of the assay was shown to be 10
copies/reaction, corresponding to 50 copies/ml plasma.
In addition, for animals whose plasma virus loads were under
the qRT-PCR detection limit, reisolation of virus from PBMC was
attempted by cocultivation of 5.0106 PBMC with 5.0106 C8166
cells for ﬁve weeks (or less for cultures that became positive).
Cultures were checked periodically for syncytia and for provirus
DNA using a set up that allows discrimination between the vac-
cination and challenge viruses (forward primer: AGCTATTTCCAT-
GAGGCGGT, reverse primers: GGGTCATCCCACTGGGAAGTTT-
GAGCTGGATGC or AAATGAGACACTGTCC).
Conﬁrmation of inhibitory levels of antiretroviral drugs in plasma
To conﬁrm that the plasma contained sufﬁcient levels of anti-
retroviral drug to suppress replication of the RT-SHIV, samples of
plasma at different dilutions were added cultures of to 2.5104
C8166 cells freshly infected with an optimal (pretitrated) amountthe virus in U-bottom microtiter culture plates. After 72 h incu-
bation, the presence of proviral DNA in cell lysates was detected by
qPCR using primers and a probe speciﬁc for the SIVmac239 nef
gene (forward primer: AGCTATTTCCATGAGGCGGT, reverse primer:
TCACAAGAGAGTGAGCTCAA, probe: [FAM] TCTGGAGATCTGCGA-
CAGAGACTCTT [BBQ]).
Identiﬁcation of escape mutants during and after the treatment phase
To identify possible escape mutants arising as a result of treatment
with Nevirapine or Efavirenz, the dominant virus populationwithin the
plasma samples was sequenced. Viral RNA was isolated from plasma
samples using the High Pure Viral RNA Kit (Roche, Penzberg, Germany)
and transcribed into cDNA using the RevertAid H Minus First Strand
cDNA Synthesis Kit (Thermo Fisher Scientiﬁc Inc., Rockford, IL, USA).
Sequencing of the reverse transcriptase from the cDNAs was performed
using HIV RT-speciﬁc primers (forward primers: TAGCCCTATTGA-
GACTGTACCAG, GTAGCATGACAAAAATCTTAGAGCCT, CACTAACAGAA-
GAAGCAGAGCT; reverse primers: CAACAGATGTTGTCTCAGCTCCTC,
CTGCTTCTGTATTTCTGCTATTAAGTC, GATTCCAGCACTGACTAATTTATC-
TAC) and the BigDyes Terminator v3.1 Cycle Sequencing Kit in com-
bination with the 3500xL Dx Genetic Analyzer for sequencing (both
from Applied Biosystems, Life Technologies Corp., Carlsbad, CA, USA).
The sequences were analyzed for mutations known to be associated
with treatment failure (i.e. escape mutations) according to the 'HIV
Drug Resistance Database' (Stanford University).
Measurement of binding antibodies
Levels of virus-speciﬁc binding antibodies were determined by
ELISA using standard protocols. Brieﬂy, ELISA plates were coated
overnight at 4 °C with SIV lysate in carbonate buffer, washed,
blocked with 2% milk powder in PBS (PM) and three-fold serial
dilutions (in PM plus 0.1% Tween-20, PMT) of the plasma samples
were added to the plates in duplicate. After one hour's incubation
at 37 °C, plates were washed and incubated with anti-human IgG
HRPO conjugate diluted 1:1000 in PMT for a further hour. Plates
were ﬁnally washed, substrate solution was added (4 mg/ml OPD
in citrate buffer plus 0.012% H2O2) and the color reaction stopped
by the addition of 5% H2SO4. Optical densities at 492 nm were
measured using a photometer. Antibody titers were determined by
calculating the dilution at which the 3rd-order polynomial line of
best ﬁt of mean ODs vs log dilution crossed the cut-off OD (0.2).
Antibody avidities were determined by ELISA as described
above but with the added step, after incubation with the plasma,
of incubating the plates with or without urea at different
concentrations.
The speciﬁcities of the antibody responses were measured by
Western blot as described previously (Towbin et al., 1979). Brieﬂy,
proteins in lysates of SIV-infected C8166 cells were separated by
10% SDS-polyacrylamide gel electrophoresis (Roth, Karlsruhe,
Germany, and Bio-Rad, Hercules, CA, USA) and transferred to PVDF
membranes (Merck Millipore, Billerica, MA, USA) by semi-dry
electroblotting. Lysates of C8166 cells were included to control
for background. Blots were incubated with plasma diluted 1:200
and then with anti-human IgG HRPO (Sigma-Aldrich Corp., St.
Louis, MO, USA) diluted 1:2000. Finally, bands were visualized
using the Pierce ECL Western Blotting Substrate (Thermo Fisher
Scientiﬁc Inc., Rockford, IL, USA) and a digital camera system.
Neutralizing antibody assay
Levels of neutralizing antibodies were determined using a yield
reduction assay adapted from a method described previously
(Nilsson et al., 1998). Brieﬂy, 32 replicates of 10 ml of each plasma
diluted 1:20 in culture medium were added to the wells of a 384-
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1:40 to 1:87480 in three-fold steps were then added to the plates,
4 replicates per dilution. After 1 h incubation at 37 °C, 30 ml of
C8166 cells (2103 cells) were added to each well and the plates
incubated for 7 days. The infected cultures were then identiﬁed
using an antigen trapping assay to detect viral p27 as described
previously (Sanders-Beer et al., 2012) and viral titers estimated
using the Spearmann–Kärber calculation. The degree of virus
neutralization (yield reduction) was calculated as the titer of virus
in the absence of plasma divided by the titer in the presence of
each plasma.
Antibody-dependent cellular cytotoxicity
The ability of the induced virus-speciﬁc antibodies to initiate
antibody-dependent cellular cytotoxity (ADCC) of virus infected
cells was determined using a modiﬁcation of the FACS-based
cytotoxicity assay described previously (Gomez-Roman et al.,
2006; Sheehy et al., 2001). Brieﬂy, CEM.NKR.CCR5 target cells were
infected by spinoculation with high-titer SIVmac and incubated for
4 days at 37 °C. Infected and uninfected cells were then labeled
with the cytoplasmic dye CFSE (Sigma) and the membrane dye
CellVue Maroon (eBiosciences). Plasma diluted 1:100 in culture
medium was added to U-96 microtiter plates in triplicate together
with 4103 infected or uninfected, double-labeled target cells.
2105 human PBMC freshly prepared from a buffy coat were then
added to each well and the plates incubated at 37 °C for 4 h. Cells
were then ﬁxed in paraformaldehyde at a ﬁnal concentration of
0.5% and the plates sealed and stored at 4 °C until FACS analysis
using a BD Calibur ﬂow cytometer ﬁtted with an HTS sampler.
FACS data were analyzed using FlowJo software (Tree Star Inc.,
Ashland, OR, USA) in which the percentage of membrane-labeled
cells that had lost their cytoplasmic dye was calculated for each
sample (%Lysis). %ADCC was calculated as the mean %Lysis in the
presence of plasma minus the mean %Lysis in the absence of
plasma (i.e. %NK).
Cytokine levels
Cytokines were quantiﬁed using Milliplex Map non-human
primate cytokine kits (Merck Millipore, Billerica, MA, USA). Ana-
lysis of 25 ml plasma samples (inactivated with a ﬁnal concentra-
tion of 0.2% Tween-20) was carried out according to the manu-
facturer's instructions. Analysis was carried out using the Bio-Plex
Multiplex System and the Bio-Plex Data Pro Software (both from
Bio-Rad, Hercules, CA, USA). The limits of detection for the assay
varied depending on the cytokine being measured, ranging from
0.5 pg/ml (IL-15) to 13.6 pg/ml (VEGF).
IFNγ ELISpot Assay
The frequency of virus-speciﬁc T-cells in PBMCs was measured
by IFNγ ELISpot using the MultiScreen HTS Assay System (Merck
Millipore, Billerica, MA, USA), an anti-human IFNγ capture anti-
body, a biotinylated anti-human IFNγ detection antibody and a
streptavidin ALP antibody (all from Mabtech AB, Nacka Strand,
Sweden). SIVmac peptides for cell stimulation were received from
the NIH, pooled in a deﬁned matrix system and incubated for 18 h
with 2.0105 PBMCs. ELISpots were stained using the AP con-
jugate substrate kit (Bio-Rad, Hercules, CA, USA) and spots counted
using an AID reader.
Tetramer staining
Identiﬁcation of CD8þ T cells recognizing the CM9 (SIVmac
Gag) peptide/Mamu-A*01 MHC-I combination was performedusing iTAg rhesus macaque tetramers (Beckman Coulter, Brea, CA,
USA) in combination with antibodies speciﬁc for CD3, CD4 and
CD8 (clones SP34-2, L200 and SK1 respectively; BD Bioscience, San
Jose, CA, USA). Tetramerþ CD8þ T cells were detected using the BD
LSR II cytometer and 1.0105 events were analyzed using the
FlowJo software.Acknowledgments
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